Sanofi and miRecule Partner to Develop Novel Antibody-RNA Conjugate for Muscular Dystrophy Therapy
By Swati Sharan
Pharma Deals Review: Vol 2022 Issue 11 (Table of Contents)
Published: 1 Nov-2022
DOI: 10.3833/pdr.v2022.i11.2743 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to broaden its rare disease franchise, Sanofi has entered into an exclusive license and collaboration agreement with miRecule to develop and commercialise an antibody-RNA conjugate, by combining the latter’s anti-DUX4 RNA therapy with Sanofi’s targeted NANOBODY technology, to treat patients suffering with facioscapulohumeral muscular dystrophy (FSHD)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS